FHTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system...

Stats
Today's Volume	111 333
Average Volume	161 853
Market Cap	221.77M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.550 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.23
ATR14	$0.0450 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Humer Kristian	Buy	275 000	Stock Option (Right to buy)
2024-04-16	Humer Kristian	Buy	0
2024-03-11	Cavalie Fanny	Sell	11 000	Common Stock
2024-01-24	Gottschalk Adrian	Buy	300 000	Stock Option (right to buy)
2024-01-24	Cardama Alfonso Quintas	Buy	60 000	Stock Option (right to buy)

INSIDER POWER
42.92
Last 90 transactions
Buy: 4 432 955 \| Sell: 2 595 211

Volume Correlation

Long: 0.13 (neutral)

Short: -0.65 (weak negative)

Signal:(42.247) Neutral

Foghorn Therapeutics Inc. Correlation

10 Most Positive Correlations
SSRM	0.88
AMRK	0.848
UMPQ	0.829
SSSS	0.812

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Foghorn Therapeutics Inc. Correlation - Currency/Commodity

-0.37
( neutral )

-0.15
( neutral )

0.00
( neutral )

-0.08
( neutral )

0.06
( neutral )

-0.17
( neutral )

Foghorn Therapeutics Inc. Financials

Annual	2023
Revenue:	$34.16M
Gross Profit:	$25.49M (74.64 %)
EPS:	$-2.34

Q4	2023
Revenue:	$5.77M
Gross Profit:	$4.92M (85.23 %)
EPS:	$-0.570

Q3	2023
Revenue:	$17.48M
Gross Profit:	$16.61M (95.06 %)
EPS:	$-0.340

Q2	2023
Revenue:	$5.60M
Gross Profit:	$3.43M (61.31 %)
EPS:	$-0.700

Financial Reports:

No articles found.

Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.